Researchers are conducting a groundbreaking trial that could revolutionize the way the body fights cancer, particularly for ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

Title: QTX3544, a potent and selective G12V-preferring KRAS inhibitor, synergizes with EGFR inhibitors for enhanced anti-tumor activity Date and Time: Wednesday, April 30, 2025; 9:00 AM - 12:00 PM ...

These inhibitors use a different mechanism of action than most other KRAS inhibitors (including that in the previous study) ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

In a $780 million deal, Servier is obtaining global rights to develop and commercialize BDTX-4933 in multiple solid tumors with RAS or RAF mutations.

These inhibitors use a different mechanism of action than most other KRAS inhibitors (including that in the previous study) to target the active or ON-state of multiple forms of RAS mutations. “The ...